Conferences - Results from #8860

ASCO GU 2018: Radium-223 Retreatment in an International, Open-label, Phase I/II Study in Patients with CRPC and Bone Metastases: 2-year Follow-up February 9, 2018

ASCO GU 2018: Abiraterone acetate plus prednisone 5 mg daily in metastatic castration-naïve prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase III trial February 9, 2018

ASCO GU 2018: Enzalutamide vs Bicalutamide in Combination with Androgen Deprivation in mHSPC February 9, 2018

ASCO GU 2018: Indirect Treatment Comparison of Abiraterone Acetate Plus Prednisone and Docetaxel on Patient-reported Outcomes in Metastatic Castration-naïve Prostate Cancer (mCNPC) February 9, 2018

ASCO GU 2018: Overall Survival of Patients with Metastatic Prostate Cancer Starting ADT with Degarelix, A Gonadotropin-releasing Hormone Antagonist February 9, 2018

ASCO GU 2018: The Clinical Role of Germline and Somatic Genomics and the Risk-Stratification of Localized Prostate Cancer February 9, 2018

ASCO GU 2018: DNA Repair Gene Panel Mutations in Young Onset Prostate Cancer Cases in The United Kingdom February 9, 2018

ASCO GU 2018: Visceral Metastases on Abiraterone vs. Placebo: A Post-hoc Analysis of Mode of Radiographic Progression In COU-AA-302 February 9, 2018

ASCO GU 2018: Occurrence of pathologic stage T3 disease at radical prostatectomy with ISUP grade group 1 (Gleason 3+3=6) prostate cancer February 9, 2018

ASCO GU 2018: Optimal Timing of Post-prostatectomy Radiotherapy For Prostate Cancer With High-risk Pathologic Features: A Multi-institutional Analysis February 9, 2018

ASCO GU 2018: Evaluation of a Predefined as Threshold in a Large Cohort of Men with Localized Prostate Cancer February 9, 2018

ASCO GU 2018: Impact of 2012 USPSTF Prostate Cancer Screening Recommendations on Prostate Cancer Detection and Presentation at Kaiser Permanente Northern California (KPNC) February 9, 2018

ASCO GU 2018: Prospective Analysis of 4,474 Prostate Biopsies to Evaluate Potential Treatment Management Impact of Combined Clinical-genomic Risk Classification February 9, 2018

ASCO GU 2018: Life After Prostate Cancer Diagnosis: One Step Beyond February 9, 2018

ASCO GU 2018: Hypoxia related mRNA biomarker to predict biochemical failure and metastasis for prostate cancer. February 9, 2018

ASCO GU 2018: Review of First Presentation: SPARTAN and PROSPER February 9, 2018

ASCO GU 2018: First Presentation - SPARTAN: A Study of Apalutamide (ARN-509) in Men with Non-Metastatic Castration-resistant Prostate Cancer February 9, 2018

ASCO GU 2018: First Presentation - PROSPER: Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) February 9, 2018

ASCO GU 2018: Transcriptomic Heterogeneity of Androgen Receptor Activity in Primary Prostate Cancer: Identification and Characterization of a Low AR-active Subclass February 9, 2018

ASCO GU 2018: Medical Resource Utilization of Abiraterone Acetate Plus Prednisone added to ADT in Metastatic Castration-naive Prostate Cancer: Results from LATITUDE February 9, 2018

Page 444 of 616